Analyzing Pfizer (PFE) and Its Rivals

Pfizer (NYSE:PFE) is one of 900 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Pfizer to related companies based on the strength of its dividends, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.

Dividends

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.3%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.7% and pay out 48.4% of their earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years.

Profitability

This table compares Pfizer and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Pfizer Competitors	-2,367.49%	-219.17%	-16.26%

Earnings & Valuation

This table compares Pfizer and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pfizer	$62.58 billion	$7.77 billion	36.16
Pfizer Competitors	$3.63 billion	$3.19 billion	548.75

Pfizer has higher revenue and earnings than its rivals. Pfizer is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Pfizer and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2	14	5	0	2.14
Pfizer Competitors	7670	13725	25531	1019	2.42

Pfizer presently has a consensus price target of $28.56, indicating a potential upside of 3.91%. As a group, “Pharmaceuticals” companies have a potential upside of 40.43%. Given Pfizer’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Pfizer has less favorable growth aspects than its rivals.

Risk & Volatility

Pfizer has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Pfizer’s rivals have a beta of -4.38, suggesting that their average share price is 538% less volatile than the S&P 500.

Institutional & Insider Ownership

68.4% of Pfizer shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pfizer beats its rivals on 8 of the 15 factors compared.

Pfizer Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.